Publication Name	World Journal of Gastroenterology
Manuscript ID	11983
Country	China

Received	2014-06-16 10:02
Peer-Review Started	2014-06-16 11:18
To Make the First Decision	2014-06-27 17:32
Return for Revision	2014-07-02 17:36
Revised	2014-07-20 22:55
Second Decision	2014-08-28 10:02
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-08-28 10:39
Articles in Press	2014-08-28 10:59
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-09-10 04:28
Typeset the Manuscript	2014-11-08 16:51
Publish the Manuscript Online	2014-11-20 20:51

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture
Manuscript Source	Unsolicited Manuscript
All Author List	Shun-Zhen Zheng, De-Jie Liu, Ping Sun, Guang-Sheng Yu, Yan-Tian Xu, Wei Gong and Jun Liu
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China 81302124
Corresponding Author	Jun Liu, Professor, Department of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, No. 324 Jingwu Road, Jinan 250021, Shandong Province, China. dr_liujun@hotmail.com
Key Words	Sorafenib; Hepatocellular carcinoma; Spontaneous rupture; Efficacy; Safety
Core Tip	Spontaneous rupture of hepatocellular carcinoma (HCC) is a life-threatening condition. Currently, sorafenib is available for HCC patients with spontaneous rupture, although its efficacy and safety have not been reported. This study aims to report the outcome of patients with ruptured HCC in a single center during a 5-year period. We retrospectively analyzed 32 patients who presented with ruptured HCC at our institute between 2008 and 2013. We concluded that sorafenib can be used in patients with ruptured HCC as it has interesting activity and is well tolerated. However, a larger prospective study is necessary to determine the efficacy of sorafenib in this group of patients.
Publish Date	2014-11-20 20:51
Citation	Zheng SZ, Liu DJ, Sun P, Yu GS, Xu YT, Gong W, Liu J. Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture. World J Gastroenterol 2014; 20(43): 16275-16281
URL	http://www.wjgnet.com/1007-9327/full/v20/i43/16275.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i43.16275

Full Article (PDF)	WJG-20-16275.pdf
Full Article (Word)	WJG-20-16275.doc
Manuscript File	11983-Review.doc
Answering Reviewers	11983-Answering reviewers.pdf
Copyright License Agreement	11983-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	11983-Language certificate.PDF
Peer-review Report	11983-Peer review.pdf
Scientific Misconduct Check	11983-CorssCheck.jpg
Scientific Editor Work List	11983-Scientific editor work list.pdf